Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis by Machahua, Carlos et al.
RESEARCH Open Access
Serum AGE/RAGEs as potential biomarker
in idiopathic pulmonary fibrosis
Carlos Machahua1,2, Ana Montes-Worboys1,2,3, Lurdes Planas-Cerezales1,3, Raquel Buendia-Flores1,
Maria Molina-Molina1,2,3*† and Vanesa Vicens-Zygmunt1,3†
Abstract
Background: The soluble receptor for advanced glycation end-products (sRAGE) has been suggested that it acts as
a decoy for capturing advanced glycation end-products (AGEs) and inhibits the activation of the oxidative stress
and apoptotic pathways. Lung AGEs/sRAGE is increased in idiopathic pulmonary fibrosis (IPF). The objective of the
study was to evaluate the AGEs and sRAGE levels in serum as a potential biomarker in IPF.
Methods: Serum samples were collected from adult patients: 62 IPF, 22 chronic hypersensitivity pneumonitis (cHP),
20 fibrotic non-specific interstitial pneumonia (fNSIP); and 12 healthy controls. In addition, 23 IPF patients were
re-evaluated after 3-year follow-up period. Epidemiological and clinical features were recorded: age, sex, smoking
habits, and lung function. AGEs and sRAGE were evaluated by ELISA, and the results were correlated with pulmonary
functional test values.
Results: IPF and cHP groups presented a significant increase of AGE/sRAGE serum concentration compared with fNSIP
patients. Moreover, an inverse correlation between AGEs and sRAGE levels were found in IPF, and serum sRAGE at
diagnosis correlated with FVC and DLCO values. Additionally, changes in serum AGEs and sRAGE correlated with %
change of FVC, DLCO and TLC during the follow-up. sRAGE levels below 428.25 pg/ml evolved poor survival rates.
Conclusions: These findings demonstrate that the increase of AGE/sRAGE ratio is higher in IPF, although the levels
were close to cHP. AGE/sRAGE increase correlates with respiratory functional progression. Furthermore, the
concentration of sRAGE in blood stream at diagnosis and follow-up could be considered as a potential prognostic
biomarker.
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Background
Idiopathic pulmonary fibrosis (IPF) is the most frequent
form of fibrotic interstitial lung diseases (ILDs), which
presents a variable outcome and is generally fatal within
2–4 years from diagnosis [1]. Histologically, IPF is char-
acterized by an usual interstitial pneumonia (UIP) pat-
tern; where honeycombing areas with collagen
deposition and fibroblast foci are situated next to struc-
turally preserved areas [2]. Advances in the knowledge
of the pathogenesis have been focused in integrating the
different factors involved in IPF with the purpose of im-
proving the diagnosis, management and treatment [3].
In clinical practice, some fibrosing lung entities such
as chronic hypersensitivity pneumonitis (cHP) and fi-
brotic nonspecific interstitial pneumonia (fNSIP) repre-
sent a challenge in the differential diagnosis for IPF as
there are clinical and radiological similarities [4–8]. Even
after an invasive procedure such as lung biopsy, it occa-
sionally remains difficult to differentiate IPF from cHP
[9, 10]. Though some features may be similar to IPF
[11], the prognosis is better for fNSIP and cHP, and the
treatment differs [12]. The proteomic analysis could be a
useful tool to differentiate between these entities and to
reach an accurate diagnosis, attempting to avoid invasive
diagnostic procedures [13]. In the last decades, serum
and broncoalveolar biological markers have been
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extensively studied in IPF for diagnosis and prognosis
[14–17]. However, despite the progress in identifying
new biomolecules involved in IPF pathogenesis, none
improve the differential diagnosis and monitoring of the
clinical course [18].
Recent studies have reported the implication of ad-
vanced glycation end-products (AGEs) and their recep-
tor (RAGE) with IPF and other fibrotic ILDs [19]. In
fact, a previous study within our group reported an
AGE-RAGE imbalance in lung tissue from IPF patients
compared to controls [20]. The RAGE is an immuno-
globulin superfamily protein [21] implicated in the
maintenance of alveolar structures in lung tissue [22]
and the development and differentiation of Type I pneu-
mocytes [23]. Its soluble form (sRAGE) is secreted dir-
ectly to the extracellular matrix (ECM) through loss of
its transmembrane region by cleavage [24, 25]. This is of
particular interest because sRAGE has been proposed as
an AGE decoy [26]. Some groups have suggested that
sRAGE bind AGEs, blocking the cell signaling pathway
of AGEs or attenuating their effects [27–29]. AGEs are
the result of non-enzymatic reactions between a redu-
cing sugar monosaccharides with a free amino group of
proteins [30], widely studied in oxidative stress, inflam-
mation and aging [31, 32]. AGEs also contribute to ab-
normal wound healing by acting on signaling pathway in
cells [33] and ECM protein cross-links [34]; these
changes may alter the physicochemical properties of col-
lagen fibers modifying the tissue stiffness [35]. Given
that RAGE is highly expressed in lung tissue [36],
sRAGE could be a possible serum or plasma biomarker
to study the pulmonary disorder.
Some studies of blood [37] and bronchoalveolar lavage
[38] indicate a correlation between lung injury and the
levels of sRAGE [39–41]. Nevertheless, there is scarce
information about the specificity of AGE-RAGE imbal-
ance in IPF [42, 43]. Therefore, our study aims to evalu-
ate the potential utility of serological AGEs and sRAGE
levels in IPF.
Methods
Ethical statement and patient recruitment
Patients were recruited in the outpatient Unit of ILDs
from University Hospital of Bellvitge: 62 IPF, 22 cHP,
and 20 fNSIP. The patient’s diagnosis was discussed in
the multidisciplinary committee and was established in
accordance with the American Thoracic Society/Euro-
pean Respiratory Society criteria [5, 12, 44]. Twelve
healthy subjects age-matched were recruited as control.
The inclusion criteria of healthy volunteers were the ab-
sence of chronic illness and pulmonary functional test
abnormalities. We collected serum samples after 3 years
from 23 IPF patients in order to analyze the changes of
AGEs-sRAGE levels and the progression of the disease.
Lung transplantation and mortality were reported. These
patients and those that return to their original care cen-
ters were excluded for the second serological evaluation.
This observational prospective study was approved by
the Ethics Committee of University Hospital of Bellvitge
(CEIC, ref. PR082/15) and all patients signed the written
informed consent before their inclusion.
Pulmonary function test (PFT)
Spirometry, lung volume, and Diffusing Capacity of
Lung for Carbon Monoxide (DLCO) were measured in
the Medisoft® bodybox Plethysmograph at the PFT la-
boratory. Three reproducible spirometry measurements
were performed (with a difference of less than 150 ml
between each one) to obtain the Forced Vital Capacity
(FVC) and Total Lung Capacity (TLC). Two maneuvers
were recorded to register the best value by DLCO
single-breath technique.
Sample collection, processing and measurement
Peripheral blood samples were collected from participants
in a BD Vacutainer® SST™ tubes (Becton, Dickinson and
Company, USA), and serum faction were obtained using
standardized procedures. AGE and sRAGE were measured
by specific commercial ELISA kit; Human RAGE
Table 1 Group features
Patient characteristics Control IPF cHP fNSIP
Subjects (n) 12 62 22 20
Gender (Male/Female) 9 / 3 53 / 9 10 / 12 5 / 15
Age (yr.) 69.11 ± 5.97 68.43 ± 8.57 64.74 ± 11.36 63.33 ± 11.62
Smoking (Former/Never) 5 / 7 43 / 19 12 / 10 5 / 15
Pack-years 20.23 ± 26.07 31.28 ± 20.74 19.25 ± 27.39 20.70 ± 11.67
Smoking cessation (yr.) 7.67 ± 9.07 15.17 ± 8.69 18.56 ± 10.38 9.00 ± 4.58
% FVC 116.20 ± 14.23** 78.71 ± 20.33 82.59 ± 15.98 81.40 ± 25.93
% DLCO 103.10 ± 2.62** 50.41 ± 20.75 56.98 ± 19.40 59.11 ± 27.67
% TLC 112.75 ± 18.31** 79.79 ± 18.69 80.88 ± 17.82 83.61 ± 19.90
Data represent the mean ± SD, cHP chronic hypersensitivity pneumonitis, DLCO diffusing capacity for carbon monoxide, fNSIP fibrotic non-specific interstitial pneumonia,
FVC forced vital capacity, IPF idiopathic pulmonary fibrosis, TLC Total lung capacity. (**) p-value < 0.01
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Quantikine ELISA Kit (DRG00; R&D Systems, USA) and
Human AGEs ELISA Kit (CSB-E09412h; Cusabio Biotech
Co., China), following the manufacturer’s recommendations.
Statistical analysis
The results were expressed as mean [SD] or median
[interquartile range] and were compared using one-way
ANOVA or Student’s t test, followed by the appropriate
post hoc analysis.
To evaluate the power of AGEs/sRAGE to discrimin-
ate between the fibrotic ILDs, receiver operating charac-
teristic (ROC) analyses were performed: the levels of
AGE and sRAGE in blood serum were considered as a
continuous variable and the diagnostic classification was
accepted as a dichotomous variable. Cutoff points were
calculated by the ROC curves with the highest possible
sensitivity and specificity, and their discriminative poten-
tial was quantified following 3 different diagnostic accur-
acy measures: Diagnostic effectiveness (Accuracy),
Likelihood ratio for positive test results (LR+), and You-
den’s index (J). To determine the serum levels that pre-
dict 3-year survival rates in the whole IPF cohort, ROC
curve analysis was also performed, and the rate was esti-
mated by Kaplan–Meier analysis using log-rank test as
statistic contrast. In addition, Pearson’s correlations were
performed to test the relation among PFT, sRAGE and
AGE serum levels at the beginning of the study and at
the end of the 3-year follow-up. Statistical software SPSS
statistic 24 (IBM, USA) was used for statistical analyses.
Significant differences were accepted when the p value
was < 0.05 (*) or < 0.01 (**).
Results
Clinical characteristics
Clinical features of IPF, cHP, fNSIP and control groups
are included in Table 1. IPF patients were predominantly
males and former smokers. No statistical differences
among the studied groups were found in age,
pack-years, nor smoking cessation. Regarding PFTs, con-
trol subjects showed better results in the percentage of
predicted FVC, DLCO and TLC than fibrotic ILDs, as
expected (p < 0.01).
AGEs and sRAGEs serum concentration in pulmonary fibrosis
AGEs levels were significantly higher in serum samples
from IPF and cHP compared with control and fNSIP pa-
tients (p < 0.01). There were no statistical differences in
AGEs serum levels between IPF and cHP groups, and no
differences were observed when fNSIP was compared to
control (Fig. 1a).
On the other hand, a significant decrease in sRAGE
concentration was observed in serum samples from IPF
and cHP patients compared to fNSIP and control donors
Fig. 1 ELISA of AGEs and sRAGE in serum blood from controls (CNT)
and fibrosing ILDs. a and b ELISA for total AGEs and sRAGE showed
significant differences between control group with IPF and cHP
(*p < 0.01), and differences between fNSIP patients with IPF (#p < 0.01)
and cHP (§p < 0.01) groups. However, there were no significant
differences between IPF with cHP and control with fNSIP. c AGEs/
sRAGE ratio estimated by ELISA was greater in IPF and cHP groups
compared with control (*p < 0.01). The ratio also allowed to distinguish
between IPF patients with cHP and fNSIP (#p < 0.05), and cHP with
fNSIP group (§p < 0.01), whereas this did not distinguish between
control and fNSIP patients. Data were analyzed by one-way ANOVA
following by the appropriate post-hoc analysis
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(p < 0.01). There were no significant differences compar-
ing IPF and cHP (Fig. 1b).
The serum AGE/sRAGE ratio of each patient was ana-
lyzed from the ELISA results. An increase of 4.20 and
4.48-fold was observed in IPF patients compared with
fNSIP and control subjects, respectively (p < 0.01).
Furthermore, the ratio was statistically significant higher
in IPF patients than cHP patients (p < 0.05). In addition,
the AGE/sRAGE ratio was 2.84-fold higher in cHP as
compared to fNSIP (p < 0.01). AGE/sRAGE ratio in
fNSIP was similar to the control group (Fig. 1c).
AGE and sRAGE as a discriminative factor between IPF
and fNSIP
We performed a ROC curve analysis to evaluate the po-
tential IPF specificity of AGEs and sRAGE levels in blood
serum (Additional file 1). The results showed that serum
sRAGE and AGEs levels present a high capacity to
differentiate IPF patients from fNSIP (AUC= 0.801 and
0.879, respectively), and between cHP and fNSIP patients
(AUC= 0.887 and 0.883, respectively) (Fig. 2a, b). Further-
more, the AGE/sRAGE ratio also distinguished between
fNSIP and IPF (AUC= 0.987, CI = 0.959–1.000), and be-
tween cHP and fNSIP (AUC= 0.882, CI = 0.766–0.998).
On the other hand, AGEs and sRAGE levels did not
demonstrate capability to differentiate IPF and cHP
(AUC= 0.383 and 0.507, respectively), while ratio showed
very low differential power (AUC= 0.713, CI = 0.569–0.856).
To evaluate the discriminative potential of AGEs,
sRAGE and AGE/sRAGE, optimal cut-off points were
obtained from the ROC curve. Table 2 showed that
AGEs/sRAGE ratio had a higher diagnostic effectiveness
(accuracy = 98.28%, LR+ = 17.00, J = 0.94) than serum
levels of AGEs and sRAGE separate values to distinguish
between IPF and fNSIP patients. Moreover, although the
diagnostic accuracy and the Youden’s index of the three
parameters were quite similar, serum levels of AGEs
were more appropriate than sRAGE and the AGEs/
sRAGE ratio to differentiate between cHP and fNSIP
(LR+ = 14.67, 4.86, and 6.38; respectively).
AGE and sRAGE correlation with PFTs
Pearson’s test showed that increased levels of AGEs cor-
related with lower sRAGE in IPF patients (r = − 0.541,
Fig. 2 ROC curve for total AGEs, sRAGE levels and Ages/sRAGE ratio. a AGEs and sRAGE showed a good capability to differentiate between IPF
patients and fNSIP group (AUC = 0.879 and 0.801, respectively), whereas the AGEs/sRAGE ratio had higher predictable capability (AUC 0.987,
CI = 0.959–1.000) to discriminate between both. b Comparing cHP and fNSIP, all the three indicators (AGEs, sRAGE levels and AGE/sRAGE ratio)
showed AUC values quite good to be considered diagnostic tests (AGEs = 0.883, sRAGE = 0.887, Ratio = 0.882). Data were evaluated by ROC
analyses; blood serum levels of AGE and sRAGE were considered as a continuous variable, and the diagnostic classification was accepted as a
dichotomous variable
Table 2 Cut-off values and diagnostic accuracy measures of AGEs, sRAGE and AGEs/sRAGE ratio
IPF – fNSIP cHP – fNSIP
Indicators AGE sRAGE Ratio AGE sRAGE Ratio
Cut-off value 19.25 μg/ml 782.59 pg/ml 25.65 ‰ 20.92 μg/ml 529.57 pg/ml 24.87 ‰
Sensitivity (%) 69.77 89.66 100.00 73.33 85.71 75.00
Specificity (%) 85.00 64.71 94.12 95.00 82.35 88.24
Accuracy (%) 74.60 84.00 98.28 85.71 83.87 81.82
LR+ 4.65 2.54 17.00 14.67 4.86 6.38
J 0.55 0.54 0.94 0.68 0.68 0.63
AGE advanced glycation end-product, cHP chronic hypersensitivity pneumonitis, fNSIP fibrotic non-specific interstitial pneumonia, J Youden’s index, LR+ Likelihood
ratio for positive test results, IPF idiopathic pulmonary fibrosis, sRAGE soluble receptor for advanced glycation end-products
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p < 0.01) (Fig. 3a). Meanwhile, cHP patients also showed a
negative correlation (r = − 0.496, p < 0.05), fNSIP patients
did not show any significant correlation (Additional file 2).
Pearson’s test also showed that lower levels of sRAGE
in serum samples from IPF patients correlated with
worse lung functionalism: % predicted of FVC (r = 0.447,
p < 0.01), DLCO (r = 0.466, p < 0.01) and TLC (r = 0.315;
p < 0.05) (Fig. 3b, c, d). However, the concentration of
AGEs did not show any correlation with PFTs in IPF
(data not shown). Regarding cHP and fNSIP samples,
there was also a positive correlation between sRAGE
and PFTs, whereas AGEs levels did not show any correl-
ation in either entity (cHP and fNSIP).
AGEs-sRAGE concentration in the follow-up of IPF patients
Twenty-three IPF patients were re-evaluated 3-years
after their inclusion. Table 3 show a decrease in the lung
functional values, with a significant decrease in the mean
FVC. Regarding ELISA analyses, only sRAGE serum
levels showed a significant decrease between the basal
level and 3-years after (p < 0.05) (Fig. 4a).
In addition, the ROC analysis of the whole IPF group
showed sRAGE levels as a reliable predictor of the 3-year
follow-up (AUC= 0.724, 95% CI = 0.586–0.863, p < 0.01).
Survival estimation by Kaplan–Meier was lower in IPF pa-
tients with serum concentrations of sRAGE under
428.25 pg/mL at the basal level (p = 0.014) (Fig. 4b).
Furthermore, we correlated the changes in serum
sRAGE and AGEs from IPF patients adjusted over time
(Δ ELISA in a month = [ELISA final – ELISA initial]/
month) with the percentage of change of lung function
in the same interval (change of % predicted PFT = [PFT
final – PFTs initial]/month). The results show a relation-
ship between variations in sRAGE, AGEs and their ratio
levels with the lung functional values (% predicted) of
FVC, TLC and DLCO (Table 4). IPF patients with a de-
crease in sRAGE serum levels during the follow-up usu-
ally showed a significant decline in % predicted DLCO
as well (Fig. 5a). On the other hand, an increase of AGEs
serum levels was highly associated with a DLCO decline,
while no changes in DLCO associated no changes in
AGEs serum levels (Fig. 5b).
With regards to the AGEs/sRAGE ratio, a negative
correlation with % predicted DLCO was observed as
well. Therefore, IPF patients with an increase of the
AGEs/sRAGE ratio had a more rapid decline in DLCO
(Fig. 5c). Furthermore, an increment of AGEs in serum
was correlated with a loss of their receptor in IPF
Fig. 3 Pearson’s correlation between sRAGE, AGEs and PFT in IPF patients. a Results showed a negative relationship between sRAGE and AGEs in
serum samples from IPF patients. b, c, d There was a positive correlation between sRAGE serum levels and percentages values of FVC, DLCO and
TLC in IPF samples. The lineal relationship between the variables was analyzed by Pearson’s correlations coefficient
Table 3 ELISA measurements and lung function from IPF
patients at 3-year interval
Patient characteristics Initial 3 yrs. p-value
sRAGE (pg/ml) 461.53 ± 191.77 375.78 ± 143.25 0.029*
AGEs (μg/ml) 19.07 ± 8.63 17.19 ± 8.45 0.340
Ratio (‰) 52.58 ± 34.58 41.13 ± 14.91 0.079
% FVC 89.21 ± 19.50 79.14 ± 20.63 0.001**
% DLCO 57.84 ± 11.54 48.68 ± 12.73 0.000**
% TLC 87.22 ± 16.89 76.47 ± 15.57 0.000**
Data represent the mean ± SD, AGE advanced glycation end-product, DLCO
diffusing capacity for carbon monoxide, FVC forced vital capacity, sRAGE
soluble receptor for advanced glycation end-products, TLC Total lung capacity.
(*) p-value < 0.05, (**) p-value < 0.01
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patients, maintaining a negative correlation over time
(Additional file 3).
Discussion
Some reports have shown an association between the
blood sRAGE levels and the state of alveolar epithelium
and lung injury [40, 45, 46]. Furthermore, previous results
from our group found AGEs increased in IPF lungs [20].
The present results suggest that serum AGEs and sRAGE
are different in IPF than in fNSIP, and their ratio is even
higher than in cHP, which could be a useful information
for the differential diagnosis of these fibrotic ILDs. More-
over, low levels of sRAGE at diagnosis predict poor sur-
vival in IPF. Finally, the AGE and RAGE changes correlate
with lung functional changes over time.
While the radiological fNSIP pattern may be similar to
IPF, the histological pattern is completely different.
Therefore, lung biopsy is required in some cases to dif-
ferentiate both entities. In this case, finding biological
lung markers that could be measured in blood samples
to differentiate both entities would be of interest for the
clinical practice. Serum AGEs and sRAGE show a com-
pletely different pattern in IPF and fNSIP, probably due
to the lack of fibroblastic foci and honeycombing in
fNSIP lungs and the pathogenic differences [11]. Lung
RAGEs are expressed in alveolar epithelial cells and
lungs with usual interstitial pneumonia pattern show
lower RAGEs expression than NSIP lungs [20]. Mani-
chaiku et al. showed lower plasma levels in IPF and HP
patients than control subjects [47]. The decrease of RA-
GEs is not present in all fibrotic ILDs; fNSIP presents
serum RAGEs and AGEs similar to normal subjects.
Lungs are the main source of RAGEs in healthy condi-
tions [36]. Several studies concluded that cleaving full
length RAGE (FL-RAGE), the transmembrane form, is
the main way to produce the soluble form of alveolar
epithelial cells (AECs) from healthy human lungs [48].
This might suggest that decrease in sRAGE found in IPF
patients could be interpreted as a lack of RAGE synthe-
sis or the loss of AECs. Thus, variations in the serum
sRAGE levels would reflect the possible changes in lung
function. The association between serum sRAGE and
PFTs, as well as the changes over time would support
this hypothesis. Longitudinal changes in FVC and DLCO
have been found to have important prognostic value in
IPF [49]. However, predicting prognosis at diagnosis
remains a challenge. In our IPF cohort, patients with lower
levels of sRAGE at the beginning of this study (under
428.25 pg/mL) showed worse lung-transplant progression
free survival rate at 3 years, in accordance with previous
observations from Yamaguchi and colleagues [37].
The decrease of sRAGE might be related to the pro-
gressive loss of alveolar structures in lung fibrosis lung.
Chronic lung diseases that cause a progressive destruc-
tion of the alveolar structures such as chronic obstruct-
ive pulmonary disease (COPD) showed low levels of
Fig. 4 Serum levels and predictive capability of sRAGE for 3-year survival rates. a Results showed a significant decrease of sRAGE in IPF patients
beyond 3-years. b Kaplan–Meier analysis showed IPF patients with sRAGE levels in serum under 428.25 pg/ml had lower survival rate (p = 0.014)
at 3-yr follow-up. Comparison of AGEs/sRAGE levels in follow-up were analyzed by Paired sample t-test, the threshold of sRAGE levels in blood
were calculated by ROC analysis and survival rate was estimated by Kaplan–Meier analysis using log-rank test as statistic contrast
Table 4 Correlation between changes in ELISA measurements
and lung function
Correlations Change of PFT r R2 P-value
Δ sRAGE FVC 0.437 0.191 0.042*
DLCO 0.586 0.343 0.005**
TLC 0.412 0.170 0.057
Δ AGEs FVC −0.452 0.204 0.027*
DLCO −0.747 0.557 0.000**
TLC −0.486 0.237 0.022*
Δ Ratio FVC −0.479 0,230 0.018*
DLCO −0.704 0.495 0.000**
TLC −0.352 0.124 0.100
AGE advanced glycation end-product, DLCO diffusing capacity for carbon
monoxide, FVC forced vital capacity, PFT pulmonary function test, r correlation
coefficient, R2 coefficient of determination, sRAGE soluble receptor for
advanced glycation end-products, TLC Total lung capacity. (*) p-value < 0.05,
(**) p-value < 0.01
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sRAGE compared with controls [39, 50]. Those results
have been correlated with a deterioration in lung func-
tion over time. Similarly, mechanical damage of lung
showed low levels of sRAGE [41, 51]. On the other
hand, the downregulation of RAGE has also been related
to several pro-fibrotic pathways [52, 53]. There are some
reports that showed a predisposition to develop a spon-
taneous pulmonary fibrosis in RAGE null mice [54]. All
these findings suggest that the destruction of alveolar
structures by fibrotic changes might favor the loss of RA-
GEs in IPF patients, and this downregulation of sRAGE,
at the same time, could favor the fibrosis progression.
Regarding AGEs levels in serum, although a significant
increase has been found in IPF and cHP compared to
fNSIP, the measurement in the IPF group at the beginning
of the study was not associated with pulmonary functional
values. However, changes in AGEs levels over time were
associated with FVC, TLC and DLCO decline. AGEs are
increased in IPF lungs and have been associated with
myofibroblast formation and ECM stiffness in vitro [55].
In addition, if sRAGE decreases, the pro-fibrotic effect of
AGEs could increase due to the decreased decoy effect
[56]. Our results also showed that those IPF patients with
higher AGEs/sRAGE ratio showed a faster decline in
DLCO. These findings indicate that an increase of AGEs
or the AGEs/sRAGE ratio might indicate the degree of re-
modeling changes due to pulmonary fibrosis.
Some limitations of the study are the small number of
the included cases in each group and the lack of validating
cohort. Furthermore, no other possible biomarkers have
been measured in our cohort in order to compare the dif-
ferences or supplementary value for diagnostic and prog-
nostic purposes. However, the results are useful for
inclusion of this biomarker in longitudinal multicenter
studies to evaluate potential biomarkers in fibrotic ILDs.
In the last few years, extensive reviews had been done
to evaluate the multiple potential serum markers pro-
posed, some of them implied in ECM remodeling or
AEC dysfunction, suggesting a much better diagnostic
accuracy and practicality when they were evaluated to-
gether [57–59]. Our model base on AGEs-sRAGE esti-
mation and ratio also emphasizes the need to mix
biomarkers for improving predictive power.
Conclusions
In conclusion, these results demonstrate that the ratio
AGEs/sRAGE could be considered as a new potential
serum biomarker for aiding in the differential diagnosis
between the most common fibrosing ILDs, although a
prospective multicenter study for validating this pivotal
results would be required. Furthermore, serum sRAGE
level is a prognostic biomarker in IPF.
Additional files
Additional file 1: ROC statistics for sRAGE and AGE serum levels. AGE:
advanced glycation end-product, AUC: area under the curve, cHP: chronic
hypersensitivity pneumonitis, fNSIP: fibrotic non-specific interstitial
A B
C
Fig. 5 Correlation between changes in DLCO and differences in sRAGE-AGEs levels in IPF patients. a In IPF patients, a decline of DLCO was
related with a decrease of sRAGE in serum (r = 0.555, p < 0.01). b and c On the contrary, AGEs levels and the AGEs/sRAGE ratio were negatively
correlated with the percentage of changes in DLCO in IPF patients (r = − 0.747 and − 0704, respectively, p < 0.01), meaning poor lung function in
patients with an increase of AGEs-sRAGE imbalance over time. The changes in serum sRAGE and AGEs and lung function from IPF patients was
calculated, adjusting over time: Δ ELISA in a month = [ELISA final – ELISA initial]/month; change of % predicted PFT = [PFT final – PFTs initial]/
month. Pearson’s correlation coefficients were performed to analyze the lineal relationship between the variables
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pneumonia, CI: confidence interval, IPF: idiopathic pulmonary fibrosis,
sRAGE: soluble receptor for advanced glycation end-products, ROC:
Receiver operating characteristic. (*) p-value < 0.05, (**) p-value < 0.01.
(XLSX 9 kb)
Additional file 2: Correlation between RAGE, AGE and PFT. AGE: advanced
glycation end-product, cHP: chronic hypersensitivity pneumonitis, DLCO:
diffusing capacity for carbon monoxide, fNSIP: fibrotic non-specific interstitial
pneumonia, FVC: forced vital capacity, IPF: idiopathic pulmonary fibrosis, r:
correlation coefficient, R2: coefficient of determination, sRAGE: soluble
receptor for advanced glycation end-products, TLC: Total lung capacity.
(*) p-value < 0.05, (**) p-value < 0.01. (XLSX 9 kb)
Additional file 3: AGEs-sRAGE correlation in IPF patients during
follow-up. IPF patients with a decline of AGEs in serum showed an
increase of soluble fragment of the receptor in blood. (PDF 109 kb)
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sRAGE: Soluble RAGE; TLC: Total Lung Capacity; UIP: Usual Interstitial Pneumonia
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